Results 221 to 230 of about 2,781,261 (274)
Some of the next articles are maybe not open access.
Pharmacokinetic studies of cholinesterase inhibitors
Acta Neurologica Scandinavica, 2009The pharmacokinetic of some centrally acting cholinesterase inhibitors that have been used to improve memory in patients with dementia of Alzheimer's type, was compared. The original compound in this class, physostigmine has an elimination half-life of 20-30 min.
M. Johansson, Agneta Nordberg
openaire +3 more sources
Ten years of cholinesterase inhibitors
International Journal of Geriatric Psychiatry, 2009AbstractIn this editorial we have summarised ten years of evidence relating to the use of cholinesterase inhibitors in Alzheimer's and other dementias. We have presented this evidence in the context of the evolution of public and professional awareness of dementia and its management and prescribing patterns over this time frame. We also briefly outline
Joanne Rodda, Zuzana Walker
openaire +3 more sources
Cholinesterase Inhibitors for Alzheimer??s Disease
Drugs, 2001Alzheimer's disease (AD) is the most common age-related neurodegenerative disease and has become an urgent public health problem in most areas of the world. Substantial progress has been made in understanding the basic neurobiology of AD and, as a result, new drugs for its treatment have become available.
John C. Morris, Jaime Grutzendler
openaire +3 more sources
ABCpred: a webserver for the discovery of acetyl- and butyryl-cholinesterase inhibitors
Molecular diversity, 2021A. Malik +3 more
semanticscholar +1 more source
The next generation of cholinesterase inhibitors
Acta Neurologica Scandinavica, 2009Clinical trials with tacrine (THA) have resulted in elevations of liver enzymes in Alzheimer patients that showed improvement. In an effort to minimize these side effects several THA analogues were synthesized. These analogues were compared to THA in biochemical as well as behavioural studies.
openaire +3 more sources
Variability in the Prescription of Cholinesterase Inhibitors and Memantine
Dementia and Geriatric Cognitive Disorders, 2009<i>Background/Aim:</i> To estimate the prevalence of Alzheimer’s disease (AD) treatment in Aragon (Spain), analyzing differences according to age, gender and health area. <i>Methods:</i> Retrospective study on AD treatment prevalence of cholinesterase inhibitors and memantine during 2005, using pharmaco-epidemiological data from
Villar-Fernández, I +3 more
openaire +5 more sources
Pulmonary mechanical responses to cholinesterase inhibitor
Fundamental and Applied Toxicology, 1989Lung static and dynamic compliances, and lung and upper airway resistances were measured in pentobarbital-anesthetized dogs before and after intravenous administration of 2 LD50 of the organophosphate cholinesterase inhibitor pinacolyl methylphosphonofluoridate (GD), followed by 1 mg of atropine 8 min later.
H. J. Bryant +2 more
openaire +3 more sources
Cholinesterase inhibitors for Alzheimer's disease
Cochrane Database of Systematic Reviews, 2006Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all ...
openaire +3 more sources
Cholinesterase Inhibitors for Alzheimer's Disease
Hospital Practice, 1998New cholinesterase inhibitors capable of slowing the progression of Alzheimer's disease are being introduced at a rapid pace. In prescribing these drugs and setting realistic expectations for outcome, it is necessary to understand that they affect cholinergic activity in other tissues as well as the brain.
openaire +3 more sources
Honey as the Potential Natural Source of Cholinesterase Inhibitors in Alzheimer’s Disease
Plant Foods for Human Nutrition, 2020E. Baranowska-Wójcik +2 more
semanticscholar +1 more source